Boston Scientific Retains Positive Ratings Following WATCHMAN FLX Trial Success

Boston Scientific (BSX) announced that its CHAMPION-AF clinical trial successfully met primary safety and efficacy endpoints for the WATCHMAN FLX device. The trial results demonstrated the device's non-inferiority compared to traditional oral anticoagulants for patients with atrial fibrillation. Following the announcement, Leerink reiterated its 'Outperform' rating on the stock, signaling continued confidence in the company's trajectory. Wells Fargo also maintained an 'Overweight' rating, though analysts characterized the clinical data as 'good, not great.' These findings validate the safety profile of the device and are expected to support incremental adoption within the medical device market. Overall, the successful trial results provide a bullish outlook for BSX as it strengthens its competitive position in cardiac care.